Name : Biotinylated Human IL-13Ra1 Protein
Product Source :
Recombinant Biotinylated Human IL-13Ra1 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala27-Thr343.[Accession | P78552-1]
Molecular Weight :
The protein has a predicted MW of 39.5 kDa. Due to glycosylation, the protein migrates to 55-75 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human IL-13Ra1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated IL-13Ra1 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Biotinylated Human IL-13Ra1, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human IL-13, hFc Tag with the EC50 of 13.8ng/ml determined by ELISA.
Background :
Two type 1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha ‘ or NR4, is now referred to as IL-13 R alpha 1. The high-affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha ‘, is now referred to as IL-13 R alpha 2.
Synonyms :
IL-13 R alpha 1; IL13R; IL13RA; CT19; IL13RA1; NR4; CD213A1; AI882074
References & Citations :
(1) Suzuki A , Leland P , Joshi B H , et al. Targeting of IL-4 and IL-13 receptors for cancer therapy[J]. Cytokine, 2015, 75(1):S1043466615002124.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
ALK-1 Protein
Annexin A2/ANXA2 Protein
Popular categories:
Serpin I2
Ubiquitin-Specific Peptidase 31